Physician profile
Robert C Hamilton
NPI 1619412012
$6,442.11
in general payments reported to CMS, 2019-2025
23 companies · $2,581 in 2025
The $2,581 reported for 2025 was more than what 95% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $413 · 2022: $611 · 2023: $648 · 2024: $2,188 · 2025: $2,581.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,417.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,417.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,020.28 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,278.27 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $883.97 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Corium, LLC | $522.27 | 2022-2024 | Azstarys |
| Alkermes, INC. | $312.04 | 2023-2025 | Aristada, Lybalvi |
| Supernus Pharmaceuticals, INC. | $304.63 | 2024-2025 | Qelbree |
| Teva Pharmaceuticals USA, INC. | $218.92 | 2024-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Axsome Therapeutics, INC. | $213.31 | 2024-2025 | Auvelity |
| Lundbeck LLC | $119.50 | 2024-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $109.87 | 2024-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $97.25 | 2022-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Ironshore Pharmaceuticals INC. | $74.82 | 2021-2022 | |
| Janssen Scientific Affairs, LLC | $52.82 | 2024-2025 | Spravato |
| Tris Pharma INC | $43.27 | 2025 | Dyanavel Xr |
| E.R. Squibb & Sons, L.L.C. | $39.97 | 2025 | Cobenfy |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $23.54 | 2024 | Trintellix |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $22.33 | 2024 | Abilify Maintena, Abilify Asimtufii |
| Antares Pharma, INC. | $21.23 | 2024 | Xyosted |
| Novo Nordisk INC | $19.74 | 2025 | Wegovy |
| Sunovion Pharmaceuticals INC. | $19.10 | 2022 | |
| Vanda Pharmaceuticals INC. | $18.98 | 2025 | Fanapt |
| Indivior INC. | $14.11 | 2022 | |
| Orexo US, INC. | $11.89 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Hamilton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.